Graham C. Fletcher
Toronto, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations.
Journal: Science advances
Published: September 07, 2022
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.
Journal: British journal of cancer
Published: April 04, 2019
Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 09, 2017
Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Journal: Bioorganic & medicinal chemistry letters
Published: April 18, 2016
Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent.
Journal: ACS medicinal chemistry letters
Published: December 14, 2015
The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.
Journal: Journal of medicinal chemistry
Published: March 13, 2015
Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 09, 2012
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 10, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026